Global type 1 diabetes market is estimated to be valued at USD 16.97 Bn in 2025 and is expected to reach USD 26.22 Bn by 2032 ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...